Immunogenicity of the nanovaccine containing intimin recombinant protein in the BALB/c mice

다국어 초록 (Multilingual Abstract)

Purpose: Escherichia coli O157:H7 is one of the most important pathogens which create hemorrhagic colitis and hemolytic uremic syndrome in human. It is one of the most prevalent causes of diarrhea leading to death of many people every year. The first diagnosed gene in the locus of enterocyte effacement pathogenicity island is eae gene. The product of this gene is a binding protein called intimin belonging to the group of external membrane proteins regarded as a good stimulants of the immune system. Chitosan with its lipophilic property is an environmentally friendly agent able to return to the environment.
Materials and Methods: Intimin recombinant protein was expressed in pET28a vector with eae gene and purification was performed using Ni-NTA and finally the recombinant protein was approved through western blotting. This protein was encapsulated using chitosan nanoparticles and the size of nanoparticles was measured by Zetasizer. Intimin encapsulated was prescribed for three sessions among three groups of oral, injection, and oral-injection using Chitosan nanoparticles. Challenge was performed for all three groups with 108E. coli O157:H7 bacteria.
Results: Intimin produced by chitosan nanoparticles improves immunological responses through the adjuvant nature of chitosan nanoparticles. Chitosan may be used as a carrier for transportation of the prescribed vaccine. Among the mice, encapsulated intimin could be able to provide suitable titers of IgG and IgA by the aid of chitosan nanoparticles. Results of mice challenge showed that decreased the bacterial shedding significantly.
Conclusion: Results showed that the chitosan nanovaccine with intimin protein may be used as a suitable candidate vaccine against E. coli O157:H7.

참고문헌 (Reference)

1 Paton AW, "Translocated intimin receptors (Tir) of Shiga-toxigenic Escherichia coli isolates belonging to serogroups O26, O111, and O157 react with sera from patients with hemolytic-uremic syndrome and exhibit marked sequence heterogeneity" 66 : 5580-5586, 1998

2 Carroll EC, "The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGASSTING-dependent induction of type I interferons" 44 : 597-608, 2016

3 Rabinovitz BC, "The intranasal vaccination of pregnant dams with Intimin and EspB confers protection in neonatal mice from Escherichia coli (EHEC) O157:H7 infection" 34 : 2793-2797, 2016

4 van Diemen PM, "Subunit vaccines based on intimin and Efa-1 polypeptides induce humoral immunity in cattle but do not protect against intestinal colonisation by enterohaemorrhagic Escherichia coli O157:H7 or O26:H" 116 : 47-58, 2007

5 Blanco JE, "Serotypes, virulence genes, and intimin types of Shiga toxin (verotoxin)-producing Escherichia coli isolates from human patients: prevalence in Lugo, Spain, from 1992 through 1999" 42 : 311-319, 2004

6 Bollag DM, "Protein methods" Wiley-Liss 1996

7 Dean-Nystrom EA, "Pathogenesis of Escherichia coli O157:H7 in weaned calves" 473 : 173-177, 1999

8 Donnenberg MS, "Pathogenesis and evolution of virulence in enteropathogenic and enterohemorrhagic Escherichia coli" 107 : 539-548, 2001

9 McNeilly TN, "Optimizing the protection of cattle against Escherichia coli O157:H7 colonization through immunization with different combinations of H7 flagellin, Tir, Intimin-531 or EspA" 10 : e0128391-, 2015

10 Fujkuyama Y, "Novel vaccine development strategies for inducing mucosal immunity" 11 : 367-379, 2012

11 Cho EJ, "Nanoparticle characterization: state of the art, challenges, and emerging technologies" 10 : 2093-2110, 2013

12 Woodrow KA, "Mucosal vaccine design and delivery" 14 : 17-46, 2012

13 Murray PR, "Medical microbiology" Mosby 429-441, 2002

14 Bertin Y, "Localization of the insertion site and pathotype determination of the locus of enterocyte effacement of shiga toxin-producing Escherichia coli strains" 70 : 61-68, 2004

15 Chaisri U, "Localization of Shiga toxins of enterohaemorrhagic Escherichia coli in kidneys of paediatric and geriatric patients with fatal haemolytic uraemic syndrome" 31 : 59-67, 2001

16 Brooks GF, "Jawetz, Melnick and Adelberg's medical microbiology" Mc-Graw Hill Medical 2010

17 Kuhne SA, "Isolation of recombinant antibodies against EspA and intimin of Escherichia coli O157:H7" 42 : 2966-2976, 2004

18 Krause G, "Investigation of domestic animals and pets as a reservoir for intimin- (eae) gene positive Escherichia coli types" 106 : 87-95, 2005

19 Ghaem-Maghami M, "Intimin-specific immune responses prevent bacterial colonization by the attaching-effacing pathogen Citrobacter rodentium" 69 : 5597-5605, 2001

20 Cornick NA, "Intimin facilitates colonization by Escherichia coli O157:H7 in adult ruminants" 70 : 2704-2707, 2002

21 Murphy BP, "In-line milk filter analysis: Escherichia coli O157 surveillance of milk production holdings" 208 : 407-413, 2005

22 Amani J, "Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice" 180 : 620-627, 2011

23 Amani J, "Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7" 28 : 6923-6929, 2010

24 van Diemen PM, "Identification of enterohemorrhagic Escherichia coli O26:H- genes required for intestinal colonization in calves" 73 : 1735-1743, 2005

25 Dziva F, "Identification of Escherichia coli O157 : H7 genes influencing colonization of the bovine gastrointestinal tract using signature-tagged mutagenesis" 150 : 3631-3645, 2004

26 Li Y, "Human response to Escherichia coli O157:H7 infection: antibodies to secreted virulence factors" 68 : 5090-5095, 2000

27 Svennerholm AM, "From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development" 133 : 188-196, 2011

28 Walker CL, "Estimating diarrhea mortality among young children in low and middle income countries" 7 : e29151-, 2012

29 Sussman M, "Escherichia coli: mechanisms of virulence" Cambridge University Press 1997

30 Dean-Nystrom EA, "Escherichia coli O157:H7 requires intimin for enteropathogenicity in calves" 66 : 4560-4563, 1998

31 Chen W, "Efficient and durable vaccine against intimin beta of diarrheagenic E. coli induced by clay nanoparticles" 12 : 1627-1639, 2016

32 Thapar N, "Diarrhoea in children: an interface between developing and developed countries" 363 : 641-653, 2004

33 Adu-Bobie J, "Detection of intimins alpha, beta, gamma, and delta, four intimin derivatives expressed by attaching and effacing microbial pathogens" 36 : 662-668, 1998

34 Potter AA, "Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins" 22 : 362-369, 2004

35 Doavi T, "Chitosan-based intranasal vaccine against Escherichia coli O157:H7" 20 : 97-108, 2016

36 Hans ML, "Biodegradable nanoparticles for drug delivery and targeting" 6 : 319-327, 2002

37 te Loo DM, "Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome" 95 : 3396-3402, 2000

38 Wales AD, "Attaching-effacing bacteria in animals" 132 : 1-26, 2005

39 Aslani MM, "An epidemiological study on Verotoxin-producing Escherichia coli (VTEC) infection among population of northern region of Iran (Mazandaran and Golestan provinces)" 18 : 345-349, 2003

40 Shariati Mehr K, "A DNA vaccine against Escherichia coli O157:H7" 16 : 133-139, 2012